HK Stock Market Move | CSPC PHARMA (01093) fell nearly 4% in the afternoon, and the net loss attributable to the parent company Stone Pharmaceutical Innovation in the first quarter increased by nearly 2.5 times compared to the same period last year.

CSPC PHARMA (01093) fell nearly 4% in the afternoon, dropping 4.88% to 8.38 Hong Kong dollars with a turnover of 668 million Hong Kong dollars as of the time of publication. On the news front, CSPC PHARMA announced that its subsidiary, CSPC Innovation Pharma, achieved operating income of 665 million yuan in the first quarter of 2026, a year-on-year increase of 40.82%; the net loss attributable to shareholders of the listed company was 93.8547 million yuan, an increase of 248.88% year-on-year. It is worth noting that CSPC PHARMA's annual performance shows that it achieved operating income of 26.006 billion yuan for the year, a year-on-year decrease of 10.4%; net profit attributable to shareholders was 3.882 billion yuan, a decrease of 10.3% year-on-year. The gross profit margin decreased from 70% in 2024 to 65.6% in 2025. This marks the third consecutive year of decline in net profit attributable to shareholders for CSPC PHARMA.